Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT06601504 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG: HMPL-760 planned dose 1
DRUG: R-GemOx
DRUG: HMPL-760 placebo planned dose 1
DRUG: HMPL-760 planned dose 2
DRUG: HMPL-760 placebo planned dose 2

Sponsor

Hutchmed